Corvus Pharmaceuticals reports clinical, financing, governance, and financial updates for a clinical-stage biopharmaceutical company developing ITK inhibition as an immunotherapy approach for immune diseases and cancer. Its lead candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit interleukin-2-inducible T cell kinase, a protein involved in T cell activation, signaling, differentiation, and function.
Recurring company news centers on soquelitinib clinical development in relapsed/refractory peripheral T cell lymphoma and atopic dermatitis, including immunologic and biomarker data presented at medical meetings. Updates also cover business results, public equity financing for research and development, board composition, and other clinical-stage pipeline disclosures.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced that Angel Pharmaceuticals has commenced a Phase 1/1b clinical trial for CPI-818, a small molecule ITK inhibitor, targeting relapsed/refractory T-cell lymphomas in China. This marks the first clinical application of CPI-818 in the region, addressing a significant unmet clinical need, as T-cell lymphomas are more prevalent in China. The trial will assess various dosing regimens and evaluate safety, tolerability, and preliminary efficacy amongst patients who have failed standard therapies.
Corvus Pharmaceuticals announced promising preclinical data for CPI-818, an ITK inhibitor aimed at preventing acute graft versus host disease (aGVHD) during allogeneic bone marrow transplantation. Presented at the ASH Annual Meeting, the study showed that CPI-818 significantly improved GVHD scores and survival rates in mouse models, leading to increased anti-inflammatory cytokines and T suppressor cells. The company is advancing CPI-818 through a Phase 1/1b clinical trial, with potential for future trials targeting refractory T-cell lymphomas and autoimmune diseases.
Corvus Pharmaceuticals (CRVS) reported promising results from its Phase 1b clinical trial of mupadolimab, a monoclonal antibody targeting CD73, in patients with relapsed refractory non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). The study demonstrated tumor regression in patients resistant to prior anti-PD-1 therapy. Corvus is expanding patient enrollment in the trial and expects to release additional data in early 2022. Mupadolimab's unique mechanism may enhance immune responses and potentially overcome resistance to existing therapies.
BURLINGAME, Calif., Nov. 10, 2021 – Corvus Pharmaceuticals (NASDAQ: CRVS) announced its participation at the Jefferies London Healthcare Conference from November 16-19, 2021. The company will engage in one-on-one meetings with investors. Additionally, a pre-recorded corporate overview presentation by CEO Richard A. Miller will be available on-demand starting at 3:00 am ET on November 18. Attendees can register for the webcast here, and the presentation will be accessible for 30 days post-event.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present data from its Phase 1/1b trial of mupadolimab at the 2021 SITC Annual Meeting, scheduled for November 10-14, 2021. The data presentation will focus on activating CD73 on B cells as a potential immunotherapy for HPV-positive head and neck cancers. A poster session will take place on November 12, 2021, and a conference call/webcast to discuss the findings is set for 9:00 am ET. Mupadolimab is a humanized monoclonal antibody designed to enhance immune response against cancers.
Corvus Pharmaceuticals (CRVS) provided a business update and reported third-quarter financial results for 2021. The company's cash and marketable securities increased to $76.3 million from $44.3 million at year-end 2020, largely due to stock offerings. Their lead drug, mupadolimab, is being tested in several trials for non-small cell lung cancer (NSCLC) and HPV+ head and neck cancers, with results expected in 2022. The company incurred a net loss of $10.7 million in Q3 2021, higher than the previous year’s $9.8 million loss, driven by increased clinical trial costs.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced the approval of its partner Angel Pharmaceuticals' IND application to initiate a Phase 1/1b clinical trial for CPI-818 in relapsed/refractory T-cell lymphomas in China. Corvus holds a 49.7% equity stake in Angel Pharma, responsible for all development costs. CPI-818 is the only clinical-stage ITK-inhibitor in China and has shown promising interim results in earlier trials. The initiative aligns with Corvus’ strategy to enhance global product development, addressing a significant healthcare need in China.
Angel Pharmaceuticals announced the approval of its IND application for CPI-818, a unique ITK inhibitor, by the Center for Drug Evaluation in China. This drug targets relapsed/refractory T-cell lymphomas and is the only ITK inhibitor in clinical development. CPI-818 has shown promising anti-tumor activity and is currently in a multi-center Phase 1b/2 trial in the U.S. and Asia. The collaboration with Corvus Pharmaceuticals provides Angel with the rights to develop and commercialize CPI-818 in China, presenting a crucial step in addressing the unmet need for effective treatments in this patient population.
Corvus Pharmaceuticals (Nasdaq: CRVS) announced positive results from a COVID-19 randomized controlled study involving 40 patients treated with mupadolimab, showing improved primary and secondary endpoints compared to placebo. The Phase 3 trial, though discontinued voluntarily, indicated a potential dose-response effect, particularly at 2mg/kg, with no reported adverse events. The company is also conducting a Phase 1b/2 trial for mupadolimab in oncology, with data expected to be presented at the SITC meeting in November.
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company (NASDAQ: CRVS), announced participation in two investor conferences in September 2021. The first event, the H.C. Wainwright Annual Global Investment Conference, is set for September 13-15, where CEO Richard A. Miller will offer a pre-recorded presentation available starting September 13 at 7:00 am ET. The second event, the Cantor Virtual Global Healthcare Conference, runs from September 27-30, with Dr. Miller presenting on September 29 from 3:20-3:50 pm ET. Webcast replays will be accessible for 90 days post-event.